News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Valeant Pharmaceuticals International (VRX) Trumps Paladin Labs Inc. (CC:PLB) for Afexa Life Sciences Inc. With $78 Million Bid


9/26/2011 8:04:39 AM

Valeant Pharmaceuticals International Inc. (TSX:VRX) said Monday it will sweeten its offer for Afexa Life Sciences Inc. to about $78 million in the escalating battle for the maker of over-the-counter remedy Cold-FX. The Toronto-area company will boost its offer to 85 cents per share, which it said is a 20 per cent premium on its previous offer of 71 cents per share made in August. Valeant is in a bidding war with Montreal-based Paladin Labs Inc. (TSX:PLB), which launched a hostile takeover bid for Afexa (TSX:FXA) in August.

Read at Canadian Business
Read at News Release
Read at CBC
Read at Globe and Mail


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES